Bracco Imaging Receives FDA Fast Track Designation for BR55 Bracco Imaging announced today that the U.S. FDA has granted Fast Track designation for the development of BR55 (perfluorobutane/nitrogen lipopeptide-coated microbubbles) injection for detecting areas of active bowel inflammation in patients with Crohn's disease.

Bracco and Zereau Join Forces for Innovative Research Program The two companies announced the launch of a study to reduce contrast media in wastewater through sustainable urine filtration systems for hospitals and diagnostic facilities.

Bracco @ ECR 2025 - Leading Sustainability in Radiology At ECR 2025, Bracco reaffirmed its commitment to innovation and sustainability in radiology with two major developments aimed at enhancing contrast media efficiency and reducing environmental impact.

The Bracco Group: Official Gold Sponsor of the Italy Pavilion at the Osaka EXPO 2025 At the Japanese World Expo, to be held from April 13 to October 13, 2025, the Bracco Group will be a key contributor on the themes of art, technology and medicine of the future.

The Bracco Foundation: A culture based on values The origins of the Bracco Foundation lie in the heritage of values passed down for nearly a century from the Bracco family and the Bracco Group, fostering a sense of Corporate Social Responsibility. The Foundation aims to create and spread expressions of culture, art, and science as means for improving our quality of life. It pays specific attention to women and younger generations, encouraging social cohesion.

Next-Gen Projects Every year, over 23,000 of the 80,000 participants to educational events organized or supported by Bracco are under the age of 35 years and over 270 fellowships are awarded thanks to partnerships with scientific societies. Together, we build bridges between generations and foster knowledge sharing. Our aim is to offer opportunities for the next generations to grow and accelerate progress in the field of medical imaging.

Bracco Imaging earns its first EcoVadis Platinum Medal: in Global Top 1%

Scientific Information Inquiry Fill in this form to receive information about medical and clinical aspects of a product.

The European Commission granted Marketing Authorisation for VUEWAY® (gadopiclenol ) for its use in pediatric patients under 2 years Bracco Imaging S.p.A., a global leader in diagnostic imaging, announces announces that on January 23, 2026, the European Commission (EC) granted the Marketing Authorisation for gadopiclenol in the European Union (EU) for pediatric patients below 2 years of age. 

The European Commission granted Marketing Authorisation for gadopiclenol for its use in pediatric patients under 2 years Bracco Imaging S.p.A., a global leader in diagnostic imaging, announces announces that on January 23, 2026, the European Commission (EC) granted the Marketing Authorisation for gadopiclenol in the European Union (EU) for pediatric patients below 2 years of age.